Skip to main content

Table 1 Characteristics of 207 patients with TAK

From: Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis

  N = 207
Age, years, mean (±SD) 39.5 ± 13.2
Female sex, n (%) 174 (84.1)
Hypertension, n (%) 100 (48.3)
Use of antihypertensive drugs, n (%) 100 (48.3)
Systolic BP, mmHg, mean (±SD) 129.3 ± 16.1
Diastolic BP, mmHg, mean (±SD) 75.6 ± 12.6
Diabetes mellitus, n (%) 19 (9.2)
Smoking, n (%) 18 (8.7)
Total cholesterol, mg/dl, mean (±SD) 180.8 ± 41.0
Triglycerides, mg/dl, mean (±SD) 112.6 ± 66.4
HDL cholesterol, mg/dl, mean (±SD) 56.1 ± 17.0
LDL cholesterol, mg/dl, mean (±SD) 102.2 ± 32.7
Framingham risk score, %, median (IQR)a 4.1 (2.5–8.0)
BMI, kg/m2, mean (±SD) 22.5 ± 3.1
Hemoglobin, g/dl, mean (± SD) 12.3 ± 1.5
Anemia, n (%) 84 (40.6)
ESR, mm/h, median (IQR) 40.0 (20.0–67.0)
CRP, mg/l, median (IQR) 4.0 (1.0–22.0)
Type of vascular involvement, n (%)
 I 48 (23.2)
 IIA 23 (11.1)
 IIB 36 (17.4)
 III 8 (3.9)
 IV 11 (5.3)
 V 81 (39.1)
Pulmonary artery involvement, n (%) 16 (7.7)
Aortic regurgitation, n (%) 61 (29.5)
Use of glucocorticoids, n (%)
 None-to-low dose 85 (41.1)
 Medium-to-high dose 122 (58.9)
Use of MTX, n (%) 126 (60.9)
Use of AZA, n (%) 38 (18.4)
Use of aspirin, n (%) 123 (59.4)
Use of statins, n (%) 123 (59.4)
Cardiovascular events, n (%) 41 (19.8)
 Coronary arterial events 23 (11.1)
 Cerebrovascular events 15 (7.2)
 Congestive heart failure 3 (1.4)
  1. TAK Takayasu arteritis, BP blood pressure, HDL high-density lipoprotein, LDL low-density lipoprotein, BMI body mass index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, MTX methotrexate, AZA azathioprine, SD standard deviation, IQR interquartile range
  2. aPatients aged < 30 years were excluded as per the formula of calculation